SecBot SecBot
8-K ·Filed Jun 3, 2026

BLFS

BIOLIFE SOLUTIONS INC
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001628280-26-040048
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor upcoming quarterly results for confirmation of the 17-20% revenue growth guidance and progress toward positive GAAP net income. The high specification rate in clinical trials (>70%) provides a long-term revenue visibility moat, but near-term execution on multi-product penetration and margin expansion will determine stock trajectory.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$27.25
T+0 close · Jun 3, 2026 · via day close
Latest settled
+36.51%
T+60 · $37.20
Vs SPY
+34.02%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $27.25entry
  2. T+1 · 6mo ago −0.59%α −0.99% · $27.09
  3. T+5 · 5mo ago −2.17%α +1.65% · $26.66
  4. T+20 · 5mo ago +3.16%α +4.16% · $28.11
  5. T+60 · 3mo ago +36.51%α +34.02% · $37.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioLife Solutions filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference. The presentation highlights FY2025 revenue of $96M (29% organic growth), 26% adjusted EBITDA margin, and provides 17-20% revenue growth guidance for FY2026, with expectations of positive GAAP net income for the full year. The filing is a routine investor relations update with no new material financial disclosures beyond previously reported figures.

Key Facts

  • FY2025 revenue of $96M with 29% organic growth
  • FY2025 adjusted EBITDA margin of 26%
  • FY2025 gross margin of 65%
  • 17-20% revenue growth guidance for FY2026
  • Expects positive GAAP net income for FY2026
  • Q1 2026 revenue of $27.5M
  • Products specified in >70% of cell-based therapy clinical trials and ~90% of commercially relevant FDA-approved cell-based therapies
  • Net cash balance of $114M as of FY2025
  • Investor presentation furnished as EX-99.1 for use at Jefferies Global Healthcare Conference

Financial Impact

FY2025 revenue $96M, 29% organic growth; FY2026 revenue growth guidance 17-20%; Q1 2026 revenue $27.5M

revenueadjusted EBITDA margingross marginnet cash

Risk Factors

  • Cell therapy market growth may not materialize as forecast
  • Customer concentration risk with large biopharma partners
  • Execution risk on multi-product penetration and margin expansion
  • Potential competitive displacement in biopreservation media

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-040048
Document: blfs-20260603.htm0001628280-26-040048
Document: 0001628280-26-040048-index-headers.html0001628280-26-040048
Document: 0001628280-26-040048-index.html0001628280-26-040048
Document: 0001628280-26-040048.txt0001628280-26-040048

Track record

15 reports on BLFS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  2. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 No price data
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 No price data
  4. Oct 16, 20264w ago 15-12G Neutral 4/10 No price data
  5. Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
  6. Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
  7. Oct 6, 20265w ago 8-K Bullish 7/10 Entry $39.00 No price data
  8. Sep 30, 20266w ago 425 Neutral 4/10 Entry $38.85 No price data
  9. Sep 30, 20266w ago DEFA14A Neutral 4/10 Entry $38.85 No price data
  10. Sep 24, 20267w ago SC 13G Neutral 4/10 Entry $38.58 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026